Kuur Therapeutics

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:awards biotechnology innovation awards
gptkbp:business_model research and development
commercialization of therapies
gptkbp:can_lead_to KTX-001
gptkbp:clinical_trial gptkb:Company
ongoing
Phase 1
Phase 2
multicenter studies
positive results
overall survival
progression-free survival
gptkbp:collaborations academic institutions
industry partners
gptkbp:committee experts in immunology
gptkbp:community_engagement patient advocacy groups
gptkbp:focus gptkb:drug
gptkbp:founded gptkb:2015
gptkbp:founder Dr. R. Scott Mc Iver
gptkbp:future_plans develop new therapies
increase funding opportunities
expand clinical trials
enhance patient access
gptkbp:headquarters gptkb:Houston,_Texas
https://www.w3.org/2000/01/rdf-schema#label Kuur Therapeutics
gptkbp:invention granted patents
gptkbp:investment gptkb:Europe
gptkb:North_America
Venture capital firms
gptkbp:language_of_instruction multiple product candidates
gptkbp:leadership experienced management team
gptkbp:mission develop innovative therapies
gptkbp:partnership gptkb:MD_Anderson_Cancer_Center
gptkbp:partnerships biopharma collaborations
gptkbp:platform gptkb:drug
gptkbp:population diverse demographics
gptkbp:publishes peer-reviewed journals
gptkbp:receives_funding_from Series A funding
Series B funding
gptkbp:regulatory_compliance gptkb:FDA
IND applications
gptkbp:research_areas oncology
personalized medicine
hematology
gptkbp:research_focus immune modulation
gptkbp:safety_features monitored closely
gptkbp:strategic_importance expand product pipeline
increase market presence
enhance clinical development
gptkbp:targets gptkb:healthcare_organization
autoimmune disorders
gptkbp:technology gptkb:drug
gptkbp:website www.kuurtherapeutics.com
gptkbp:bfsParent gptkb:Athenex
gptkbp:bfsLayer 3